Year 5 Moonlitic Total Revenue (per CEO 5-year projection)
$12.1B
$125M Council + $1.1B Platform Licenses + $75M Tile Builders + $10.4B Data Sales (20%) + $500M Payments
Five-year arc: Y1 $25M → Y2 $305M → Y3 $1.6B → Y4 $5.3B → Y5 $12.1B. Plus $12.76B+ flowing annually to patients via 80/20 cascade at 1% US-population marketplace penetration.
🏛
Change Council Member Subscription
Stream 1 · annuity · enterprise · partner-of-record
$5M / yr
per Member
Industry leaders join the Change Council to shape data-asset economy standards and economics. Members partner-of-record with the platform; gain influence over governance, early signal on data trends, and license rights to provision their workforce with Platform Licenses (Stream 2). Brand asset for the Member organization, not a cost line.
Members × $5M/yr
Y1 target: 2 Members × $5M = $10M · Y5: 25 Members × $5M = $125M
Members: Self-insured Fortune-500 employers, large health systems, pharma R&D leadership, payer innovation teams, government health agencies.
Y1 target: Enroll 2 Change Council Members (per CEO 5-year projection).
👥
Enterprise-Wide Licenses
Stream 2 · per-seat subscription · employee + covered lives
$250 / yr
per employee or covered customer
Change Council Members purchase licenses for their workforce — employees + covered lives — at a $250/yr retail price. Each license unlocks Platform access (gather + control + monetize personal health data, longitudinal record, clinician portal, trial matching, earnings cascade). Distributed inside the Member's existing benefits portal.
Members × employees-per-Member × $250
Assumption: 1 company ≈ 100K users (employees + covered lives)
Y2 (CEO projection): $250M · Y3: $525M · Y5: $1.1B (blended with Stream 3)
Distribution: Inside the Council Member's open-enrollment / benefits portal — zero CAC.
Why workforce opts in: earnings cascade + trial matching + longitudinal record + clinician portal access in one place. The employee owns the data, employer just provides access.
🎗
Direct-to-Consumer Licenses
Stream 3 · D2C · activated via communities + tumor registries
$300 / yr
per consumer · Core Membership tier
Direct-to-consumer licenses activated through
disease-specific communities and tumor registries — patients sign up directly via
moonlitic.com waitlist, bypassing the Council/employer middleman. Critical for retired, uninsured, self-pay, and oncology patients not covered by a Council Member.
D2C consumers × $300
Y3 target: 500K consumers × $300 = $150M / yr
Blended with Stream 2 in CEO projection: Y2 $250M · Y3 $525M · Y5 $1.1B (Streams 2+3 combined)
Activation channels: SEER · state cancer registries · hospital tumor registries · disease foundations (LLS, Susan G. Komen, NORD) · patient communities (rare-disease forums, Facebook groups).
Why this works: tumor registries are already-curated patient lists, motivated and engaged. Lifetime value high; CAC low because the registry is the channel.
🧩
Marketplace — Tile Builders
Stream 4 · per-tile annual fee · 80% to Tile Builder · 20% Moonlitic
$500K + $XXX,XXX
initial integration fee + annual maintenance
Member firms create Tiles — apps, analytics, and services that run on the Moonlitic Platform. Each Tile pays a one-time $500K integration fee plus $XXX,XXX/yr maintenance. Of the gross revenue Tiles generate, 80% returns to the Tile Builder; Moonlitic keeps 20%. Sold to Change Council Members and Tile Builders only.
Tiles × ($500K init + $XXX,XXX/yr) + 20% of Tile gross revenue
CEO Y2: $5M · Y3: $26M · Y4: $49M · Y5: $75M
Target: pilot rollout in 2027.
Tile Builder types: Pharma · Life Sciences · CROs · Payers · Self-insured employers · Health systems · Provider networks · Public health agencies · Academic researchers · Med-device makers · Digital health partners (11 buyer-type lanes).
Gating: entitlement matrix enforces what each Tile can access (Insurer cannot license Genetic · Drug Mfgr cannot license Clinical detail · nobody licenses SUD).
💎
Data Sales to Subscribers
Stream 5 · marketplace transactions · 80% to patient · 20% Moonlitic
$15.95B
total gross marketplace at 1% US-population penetration · 3 sales/year/user
Per-condition marketplace pricing per CEO Pg 26 source-of-truth. Weighted-average across the full mix is ~$643/sale. Of every gross transaction, 80% returns to the patient; Moonlitic keeps 20%. Sold to Change Council Members and Tile Builders only. SUD (42 CFR Part 2) records categorically excluded.
Per-condition pricing (CEO Pg 26 · 1% pen · 3 sales/yr)
EHR Data
avg $550
3M users · $4.95B gross
Genomic Data
avg $3,000
500K users · $4.5B gross
Rare Disease
avg $2,750
300K users · $2.475B gross
Cardiology
avg $275
1.2M users · $990M gross
Oncology
avg $1,400
180K users · $756M gross
Mental Health
avg $330
600K users · $594M gross
Digital Health
avg $105
1.5M users · $472M gross
Chronic Pain
avg $220
520K users · $343M gross
Diabetes
avg $275
400K users · $330M gross
Dementia
avg $825
70K users · $173M gross
Total marketplace gross at 1% US population penetration
→ $12.76B to patients (80%) + $3.19B Moonlitic (20%) = $15.95B annually
CEO 5-year arc · Moonlitic 20% take: Y3 $983M · Y4 $3.8B · Y5 $10.4B
Source: CEO pitch deck Pg 26, "WHAT IS OUR DATA ACTUALLY WORTH?" — table assumes ONLY 1% penetration of US population, ONLY 3 purchases per user data set per year. Real upside scales with penetration above 1% and frequency above 3.
Compliance gating: SUD (42 CFR Part 2) records categorically excluded from marketplace.
💳
Payments Optimization
Stream 6 · system-wide savings · 1% of US claims volume
$500M – $1.5B
at 1%–3% fee on $50B/yr in payments processed
Moonlitic's Payments product manages data payments and reimbursements securely and transparently. Auditability tracks and eliminates waste, fraud, and abuse — addressing $1T of waste in the $4.9T US healthcare spend. Includes user payments (Velo ACH), claims reimbursement optimization, and provider settlement.
$50B annual payment volume × 1%–3% fee
That's 1% of US payment volume/year. → $500M low-end · $1.5B high-end
CEO Y4–Y5: $500M/yr. Excludes system-wide savings (waste/fraud/abuse reduction).
What it does: claim payment routing · denial management · reimbursement optimization · payment audit trail · DENY-tactic elimination via transparent reconciliation. Velo Payments rail handles patient ACH; this stream handles the broader payer↔provider↔patient flow.
Code today: not yet built. F06 covers patient payouts (Velo); the broader Payments Optimization service is a planned product line in Block C+.
On every marketplace data sale (Stream 5): Moonlitic keeps 20% of NET, the patient gets 80% of NET. Per-transaction platform costs (Velo ACH, audit ledger, tax admin) come off GROSS — they never come out of the patient's 80%.
This is the same money as Stream 5 — not an additional revenue line. It's the rule that converts Stream 5 marketplace volume into Moonlitic 20% revenue + patient 80% earnings. We surface the rule separately because it is the platform's trust mechanism: the patient can see it, the buyer can see it, the auditor can see it.
Buyer pays GROSStile fee · per-record fee · cohort acceptance
100%
$50,000.00
– Velo Payments feeACH disbursement · KYC · 1099-NEC tax cert
~0.5%
−$250.00
– Audit ledger write feeAzure Confidential Ledger entry
~0.1%
−$50.00
– Tax admin reservewithholding · 1099 preparation
~0.4%
−$200.00
NET available for splitafter platform-cost line items
99.0%
$49,500.00
→ Patient (80% of NET)ACH within 3 business days · transparent line-item
80%
$39,600.00
→ Moonlitic (20% of NET)platform revenue · Stream 5 · part of Moonlitic ARR
20%
$9,900.00
1. Six revenue streams, not one
Council Memberships are annuity revenue — predictable, contracted, multi-year. Platform Licenses (B2B + D2C) are scaling revenue tied to consumer growth. Tile Builder Fees + Data Sales 20% are marketplace upside. Payments Optimization is a separate $500M+ revenue line on $50B in payment volume. Investor sees three steady lines + three scaling lines + one ceiling-high marketplace line.
2. Patient share is a moat, not a cost
The 80% to patient is what differentiates Moonlitic from Datavant / Komodo / IQVIA. They keep ~100%. Moonlitic gives the patient a meaningful share — that's why patients refer and consent at scale. The 80% is acquisition + retention spend disguised as compensation.
3. Two zero-CAC distribution channels
B2B: Council members enroll their workforce through existing benefits portals. B2C: tumor registries and disease communities are pre-curated patient lists that activate at $300/yr direct. Both channels are essentially zero-paid-acquisition for the patient side.
4. Specialty wedge — Oncology first
Oncology longitudinal records command $30K–$50K each (Stream 5). Plus: tumor registries are the perfect B2C activation channel for Stream 3. Specialist density is high (~12K oncologists US-wide), pharma trial spend is concentrated in oncology (~40%+), and consent quality is high (patients are highly motivated). Land the wedge, then expand to rare disease + mental health + cardio.
5. Compliance moat compounds
Every regulator (federal × state × standards × audit frameworks) is a barrier-to-entry. New entrants spend years to reach where Moonlitic is today. See Compliance Moat.
6. Three product lines, not one
Beyond data marketplace: clinical trials matching (sponsor cohort fees) + payments solutions (white-label patient-disbursement product). Each product line independently scales. Investors get three businesses for one valuation.